Table 4.

First‐line treatment plans by country and cohort

	Overall			France			Germany			Italy			UK
	All	Early	Recent	All	Early	Recent	All	Early	Recent	All	Early	Recent	All	Early	Recent
All regimens, N	836	592	244	269	176	93	213	156	57	136	95	41	218	165	53
To progression, %	13	12	17	23	18	32	11	12	7	10	10	10	6	6	8
Fixed duration, %	66	66	65	64	68	55	63	58	77	78	77	81	62	64	59
To best response, %	21	23	18	14	14	13	26	30	16	13	14	10	31	30	34
IMID‐based, N	80	40	40	37	14	23	20	12	8	6	0	6	17	14	3
To progression, %	46	33	60	62	43	74	45	42	50	33	0	33	18	14	33
Fixed duration, %	15	23	8	14	21	9	10	17	0	17	0	17	24	29	0
To best response, %	39	45	33	24	36	17	45	42	50	50	0	50	59	57	67
PI‐based, N	119	86	33	51	36	15	23	14	9	9	7	2	36	29	7
To progression, %	21	23	15	29	31	27	17	29	0	22	29	0	11	10	14
Fixed duration, %	50	50	52	29	31	27	78	64	100	67	57	100	58	66	29
To best response, %	29	27	33	41	39	47	4	7	0	11	14	0	31	24	57
Alkylator, N	67	61	6	16	12	4	32	32	0	8	6	2	11	11	0
To progression, %	28	23	83	75	67	100	16	16	0	25	17	50	0	0	0
Fixed duration, %	60	64	17	25	33	0	72	72	0	63	67	50	73	73	0
To best response, %	12	13	0	0	0	0	13	13	0	13	17	0	27	27	0
PI/alkylator‐based, N	336	232	104	104	72	32	89	65	24	105	75	30	38	20	18
To progression, %	4	5	3	2	1	3	5	6	0	6	7	3	5	5	6
Fixed duration, %	85	82	91	95	96	94	75	68	96	85	81	93	76	75	78
To best response, %	11	14	6	3	3	3	20	26	4	10	12	3	18	20	17
IMID/alkylator‐based, N	183	151	32	34	29	5	37	32	5	3	3	0	109	87	22
To progression, %	5	5	6	9	7	20	3	3	0	0	0	0	5	5	5
Fixed duration, %	62	63	56	79	79	80	35	38	20	67	67	0	65	67	59
To best response, %	33	33	38	12	14	0	62	59	80	33	33	0	30	29	36
Oral, N	80	40	40	37	14	23	20	12	8	6	0	6	17	14	3
To progression, %	46	33	60	62	43	74	45	42	50	33	0	33	18	14	33
Fixed duration, %	15	23	8	14	21	9	10	17	0	17	0	17	24	29	0
To best response, %	39	45	33	24	36	17	45	42	50	50	0	50	59	57	67
Injectable, N	489	336	153	179	120	59	113	80	33	118	85	33	79	51	28
To progression, %	9	10	6	11	12	10	7	10	0	7	8	3	8	8	7
Fixed duration, %	76	73	82	75	75	76	76	68	97	83	79	94	67	69	64
To best response, %	15	17	12	13	13	14	17	23	3	10	13	3	25	24	29

Treatment plan of PI/IMID‐based treatments (N = 34) and other regimens (N = 17) not listed due to space and low sample size.

Abbreviations: IMID, immunomodulatory drug; PI, protease inhibitor; UK, United Kingdom.